+39 02 610346.1 - info@newron.com

Investors and Media

Investors and Media

Newron Pharmaceuticals is headquartered in Bresso, Italy and its shares are listed on SIX Swiss Exchange under the ticker symbol NWRN. Newron is committed to providing reliable and transparent information about our business in an open and timely manner. This area contains investment and shareholder information, including our latest share price, key financial data and presentations and webcasts.


Newron news see all

Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease


Newron Pharmaceuticals hosts its 2018 R&D Day in New York City

Investment Plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m


Meiji Seika and Eisai announce submission of manufacturing and marketing approval application in Japan for safinamide in Parkinson’s disease

Newron Pharmaceuticals Announces Prominent Medical Experts to Present at its 2018 R&D Day on October 31 in New York


Stock information

Download centre

Email alerts






Upcoming Eventssee all

German Equity Forum 2019

November, 25-27, 2019 -Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt, Germany

10th Annual Jefferies 2019 London Healthcare Conference

November 20-21, 2019 - the Waldorf Hilton, London, UK

Investora Zürich 2019

September 18-19, 2019 - Samsung Hall, Dübendorf, Switzerland